This article was originally published in The Gray Sheet
Executive SummaryPhase I safety investigational new drug application trial of firm's liposomal drug-delivery spheres for use with the Microfocus BPH 800 microwave urethroplasty system will commence following FDA clearance, firm says April 8 (1"The Gray Sheet" Oct. 26, 1998, p. 19). Study will examine heated liposome delivery of Pharmacia's Adriamycin (doxorubicin) in the treatment of prostate cancer. Technology was developed at Duke University and is licensed exclusively to Celsion...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.